Is BNTX or IMVT more profitable?

Immunovant has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -44.39% -5.30% -4.62% Immunovant N/A -65.66% -59.88%

Does the media prefer BNTX or IMVT?

In the previous week, BioNTech and BioNTech both had 4 articles in the media. Immunovant's average media sentiment score of 1.65 beat BioNTech's score of 1.38 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor ROIV or IMVT?

In the previous week, Roivant Sciences had 7 more articles in the media than Immunovant. MarketBeat recorded 11 mentions for Roivant Sciences and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.65 beat Roivant Sciences' score of 1.59 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Immunovant 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is IMVT or INSM more profitable?

Immunovant has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Immunovant's return on equity of -65.66% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% Insmed -144.44% -130.11% -51.57%

Does the media favor IMVT or INSM?

In the previous week, Insmed had 16 more articles in the media than Immunovant. MarketBeat recorded 20 mentions for Insmed and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.65 beat Insmed's score of 1.22 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Insmed 13 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMVT or MRNA more profitable?

Immunovant has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% Moderna -143.55% -26.64% -19.32%

Does the media prefer IMVT or MRNA?

In the previous week, Moderna had 13 more articles in the media than Immunovant. MarketBeat recorded 17 mentions for Moderna and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.65 beat Moderna's score of 0.57 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Moderna 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Immunovant (IMVT) Competitors

$33.62 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$33.67 +0.05 (+0.16%)

As of 06/12/2026 07:48 PM Eastern

Compare

IMVT vs. SLNO, BNTX, ROIV, INSM, and MRNA

Should you buy Immunovant stock or one of its competitors? MarketBeat compares Immunovant with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immunovant include Soleno Therapeutics (SLNO), BioNTech (BNTX), Roivant Sciences (ROIV), Insmed (INSM), and Moderna (MRNA). These companies are all part of the "medical" sector.

How does Immunovant compare to Soleno Therapeutics?

Soleno Therapeutics (NASDAQ:SLNO) and Immunovant (NASDAQ:IMVT) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

Soleno Therapeutics has a net margin of 33.70% compared to Immunovant's net margin of 0.00%. Soleno Therapeutics' return on equity of 22.85% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soleno Therapeutics	33.70%	22.85%	18.25%
Immunovant	N/A	-65.66%	-59.88%

Soleno Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soleno Therapeutics	$285.01M	9.69	$20.89M	$1.77	29.95
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 6.4% of Soleno Therapeutics shares are held by company insiders. Comparatively, 1.8% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Immunovant had 4 more articles in the media than Soleno Therapeutics. MarketBeat recorded 4 mentions for Immunovant and 0 mentions for Soleno Therapeutics. Immunovant's average media sentiment score of 1.65 beat Soleno Therapeutics' score of 0.94 indicating that Immunovant is being referred to more favorably in the news media.

Company	Overall Sentiment
Soleno Therapeutics	Positive
Immunovant	Very Positive

Soleno Therapeutics presently has a consensus target price of $76.67, suggesting a potential upside of 44.63%. Immunovant has a consensus target price of $37.33, suggesting a potential upside of 11.05%. Given Soleno Therapeutics' higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Soleno Therapeutics has a beta of -2.22, suggesting that its stock price is 322% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

Summary

Soleno Therapeutics beats Immunovant on 10 of the 15 factors compared between the two stocks.

How does Immunovant compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

BioNTech presently has a consensus target price of $129.56, indicating a potential upside of 43.10%. Immunovant has a consensus target price of $37.33, indicating a potential upside of 11.05%. Given BioNTech's stronger consensus rating and higher probable upside, equities research analysts clearly believe BioNTech is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

15.5% of BioNTech shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 1.8% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, BioNTech and BioNTech both had 4 articles in the media. Immunovant's average media sentiment score of 1.65 beat BioNTech's score of 1.38 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Immunovant has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Immunovant	N/A	-65.66%	-59.88%

Immunovant has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.05	-$1.29B	-$5.88	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

BioNTech has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

Summary

BioNTech beats Immunovant on 9 of the 15 factors compared between the two stocks.

How does Immunovant compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

In the previous week, Roivant Sciences had 7 more articles in the media than Immunovant. MarketBeat recorded 11 mentions for Roivant Sciences and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.65 beat Roivant Sciences' score of 1.59 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Immunovant	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Roivant Sciences has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Comparatively, 1.8% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Roivant Sciences currently has a consensus target price of $33.59, suggesting a potential upside of 11.82%. Immunovant has a consensus target price of $37.33, suggesting a potential upside of 11.05%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Roivant Sciences is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Immunovant has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Immunovant	N/A	-65.66%	-59.88%

Roivant Sciences has higher revenue and earnings than Immunovant. Roivant Sciences is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	2,615.84	-$299.77M	-$0.60	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

Summary

Roivant Sciences beats Immunovant on 12 of the 15 factors compared between the two stocks.

How does Immunovant compare to Insmed?

Immunovant (NASDAQ:IMVT) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

Immunovant has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Insmed	$606.42M	34.97	-$1.28B	-$5.75	N/A

In the previous week, Insmed had 16 more articles in the media than Immunovant. MarketBeat recorded 20 mentions for Insmed and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.65 beat Insmed's score of 1.22 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Insmed	13 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

47.1% of Immunovant shares are owned by institutional investors. 1.8% of Immunovant shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Immunovant currently has a consensus target price of $37.33, suggesting a potential upside of 11.05%. Insmed has a consensus target price of $212.50, suggesting a potential upside of 117.17%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Immunovant has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Insmed has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

Immunovant has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Immunovant's return on equity of -65.66% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Insmed	-144.44%	-130.11%	-51.57%

Summary

Insmed beats Immunovant on 9 of the 16 factors compared between the two stocks.

How does Immunovant compare to Moderna?

Immunovant (NASDAQ:IMVT) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, institutional ownership, earnings, profitability, valuation and risk.

Immunovant presently has a consensus price target of $37.33, suggesting a potential upside of 11.05%. Moderna has a consensus price target of $36.60, suggesting a potential downside of 26.67%. Given Immunovant's stronger consensus rating and higher possible upside, equities analysts clearly believe Immunovant is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Immunovant has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Moderna	-143.55%	-26.64%	-19.32%

47.1% of Immunovant shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 1.8% of Immunovant shares are held by insiders. Comparatively, 10.8% of Moderna shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Immunovant has higher earnings, but lower revenue than Moderna. Immunovant is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Moderna	$1.94B	10.19	-$2.82B	-$8.15	N/A

Immunovant has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Moderna has a beta of 1.05, meaning that its stock price is 5% more volatile than the broader market.

In the previous week, Moderna had 13 more articles in the media than Immunovant. MarketBeat recorded 17 mentions for Moderna and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.65 beat Moderna's score of 0.57 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Moderna	9 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

Moderna beats Immunovant on 8 of the 15 factors compared between the two stocks.

Get Immunovant News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMVT vs. The Competition

Export

Metric	Immunovant	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.90B	$3.39B	$6.53B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-12.09	20.00	23.99	24.42
Price / Sales	N/A	306.82	513.41	111.24
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	8.02	8.32	10.73	6.82
Net Income	-$505.61M	$23.94M	$3.57B	$337.56M
7 Day Performance	9.16%	1.84%	0.59%	1.17%
1 Month Performance	22.30%	-0.04%	1.54%	3.16%
1 Year Performance	114.69%	44.82%	25.42%	30.58%

Immunovant Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMVT Immunovant	3.006 of 5 stars	$33.62 flat	$37.33 +11.0%	+114.7%	$6.90B	N/A	N/A	120	Positive News Gap Down
SLNO Soleno Therapeutics	4.4041 of 5 stars	$53.01 flat	$76.67 +44.6%	N/A	$2.76B	$285.01M	29.95	30
BNTX BioNTech	4.5696 of 5 stars	$85.50 -2.9%	$129.56 +51.5%	-15.0%	$22.27B	$3.25B	N/A	7,807	Positive News
ROIV Roivant Sciences	2.2976 of 5 stars	$28.49 -0.3%	$33.59 +17.9%	+165.4%	$20.56B	$8.26M	N/A	860	Positive News
INSM Insmed	3.4231 of 5 stars	$94.17 -0.1%	$212.50 +125.7%	-0.9%	$20.42B	$606.42M	N/A	1,664	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMVT) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunovant (IMVT) Competitors

IMVT vs. SLNO, BNTX, ROIV, INSM, and MRNA

How does Immunovant compare to Soleno Therapeutics?

Summary

How does Immunovant compare to BioNTech?

Summary

How does Immunovant compare to Roivant Sciences?

Summary

How does Immunovant compare to Insmed?

Summary

How does Immunovant compare to Moderna?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMVT vs. The Competition

Immunovant Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunovant (IMVT) Competitors

IMVT vs. SLNO, BNTX, ROIV, INSM, and MRNA

How does Immunovant compare to Soleno Therapeutics?

Is SLNO or IMVT more profitable?

Which has better valuation and earnings, SLNO or IMVT?

Do institutionals and insiders have more ownership in SLNO or IMVT?

Does the media refer more to SLNO or IMVT?

Do analysts rate SLNO or IMVT?

Which has more risk and volatility, SLNO or IMVT?

Summary

How does Immunovant compare to BioNTech?

Do analysts prefer BNTX or IMVT?

Do institutionals and insiders believe in BNTX or IMVT?

Does the media prefer BNTX or IMVT?

Is BNTX or IMVT more profitable?

Which has better earnings and valuation, BNTX or IMVT?

Which has more risk & volatility, BNTX or IMVT?

Summary

How does Immunovant compare to Roivant Sciences?

Does the media favor ROIV or IMVT?

Which has more risk & volatility, ROIV or IMVT?

Do insiders & institutionals believe in ROIV or IMVT?

Do analysts recommend ROIV or IMVT?

Is ROIV or IMVT more profitable?

Which has better earnings and valuation, ROIV or IMVT?

Summary

How does Immunovant compare to Insmed?

Which has higher earnings & valuation, IMVT or INSM?

Does the media favor IMVT or INSM?

Do institutionals and insiders hold more shares of IMVT or INSM?

Do analysts prefer IMVT or INSM?

Which has more risk & volatility, IMVT or INSM?

Is IMVT or INSM more profitable?

Summary

How does Immunovant compare to Moderna?

Do analysts recommend IMVT or MRNA?

Is IMVT or MRNA more profitable?

Do insiders and institutionals hold more shares of IMVT or MRNA?

Which has preferable valuation and earnings, IMVT or MRNA?

Which has more risk & volatility, IMVT or MRNA?

Does the media prefer IMVT or MRNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMVT vs. The Competition

Immunovant Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools